Instituto Butantan, in partnership with Sinovac Biotech, is pleased to announce CoronaVac Symposium, an international online event that aims to promote and discuss the latest results of the efficacy and security of CoronaVac and the scientific fundamentals of the effectiveness study Project S, that took place in the city of Serrana.
The scientific meeting will bring together specialists from Brazil, United States, Turkey, Chile, China and Spain who will promote deep and qualified dialogues. Among the topics discussed are: the history of the vaccine that, till this moment, is the most administered in the world protecting people from Covid-19, CoronaVac, and its immunogenicity among elderly and pediatric population; positive responses to the third dose or booster dose and the questions about immunization time in different countries.
This is a free online event, open to the general public. The lectures will have a simultaneous translation into Portuguese and English.
The main subject in the first day is the CoronaVac development as a historical mark of international immunization to combat the SAR-CoV-2 virus, from the first base researches to the last outcomes of effectiveness and security showed in Project S, Serrana, in São Paulo and in other countries. The opening session of the symposium will be held by the president of Butantan Institute, Dimas Covas and the president of Sinovac Biotech, Weidong Yin.
The CoronaVac underpinning Science about immunogenicity and security of the booster dose of vaccination with the inactivated SARS-CoV-2 will be presented on the second day of the international online symposium. The research outcomes will show the outreach, the potency and duration of CoronaVac immunization in several countries.
The symposium closing session will highlight the immunization outcomes among different groups of population, especially the clinic trials among patients with comorbidities, elderly, children and adolescents.
Pediatric Infectious Diseases specialist in İstanbul Memorial Hospitals Group, completed his M.D. degree followed by a pediatrics residency from the Hacettepe University Medical Faculty, Ankara, Turkey. Attended as an observer doctor in the Chicago University Hospital Pediatric Infectious Diseases Department and worked as a co-investigator in the World Health Organization granded project for diagnosis of tuberculosis infection. He dedicated his time for research related to COVID-19 infections in children and acceptance and immunogenicity of COVID-19 vaccines.
Full Professor at the Department of Molecular Genetics and Microbiology, School of Biological Sciences and the Department of Endocrinology, School of Medicine, at the Pontificia Universidad Católica de Chile. He is also Visiting Faculty at The Albert Einstein College of Medicine in New York, The University of Nantes in France and the University of Iowa. He obtained his MSc and PhD in Microbiology and Immunology from the Albert Einstein College of Medicine in New York and published over 260 articles in leading journals and over 40 patent applications.
Graduated in Medicine from the Medical School of Ribeirão Preto, University of São Paulo and has Master and PhD in Medicine from the same university, where he has been full professor of Clinical Medicine, Hematology and Transfusion Medicine, since 1999. He is director of the Butantan Institute, director-president of Regional Blood Center of Ribeirão Preto and member of the Advisory Committee of the Strategic Committee for Transplantation and Organ Donation Affairs of the Ministry of Health and of the Technical Chamber of the Blood and Hemodynamic Coordination of the Ministry of Health.
Full professor of virology and Head of the Microbiology at Institute of Biomedical Science at University of São Paulo, Brazil. He works as Guest Research at Center for Disease Control and Prevention in Atlanta, USA. He has authored/co-authored over 200 peer-reviewed papers, including major articles, letters and book chapters. His laboratory is dedicated to innovation and development of new strategies for treatment and diagnosis for emerging viruses of importance in public health with a special view on SARS-CoV-2, Influenza and other viruses.
Full Professor of Rheumatology, Head of the Division of Rheumatology and Clinical Director of Hospital das Clínicas, Medical School of the University of São Paulo. She graduated and undertook specialist training in Rheumatology at the Medical School of the University of São Paulo, followed by a four years rheumatology research fellowship at the Hospital for Special Surgery, New York, USA. She has published more than 300 original papers indexed in PubMed and several book chapters, several of them on vaccine immunogenicity and safety in autoimmune disorders.
Infectologist doctor, he is full professor at the Division of Infectious and Parasitic Diseases at the Faculty of Medicine by the University of São Paulo (FMUSP). He performs translation medicine projects, bringing basic science concepts to clinical applications, especially in infectious diseases. Currently he is the Director of Clinical Research Center at Hospital das Clínicas of FMUSP
Full professor of infectious disease in School of Public Health, Fudan University, China. His research interests include the transmission dynamics, epidemiological parameters, disease burden, evaluation of interventions, as well as vaccine efficacy, effectiveness, safety, and cost effectiveness for emerging and re-emerging infectious diseases with public health importance, e.g., COVID-19, influenza, HFMD, and so on. Prof. Yu has published over 200 articles in international peer-review journals.
She has a Bachelor of Engineering, focused on bioengineering and a Master of Science on Biochemistry and Molecular Biology from China Pharmaceutical University. She has a Master of Public Health on health policy and management at Emory University, Atlanta. She was a researcher at Beijing Tibetan Hospital, a Data Analyst at Rollins School of Public Health at Emory University and Emory Healthcare. Was a Pharmacovigilance specialist at Sinovac and now is Pharmacovigilance Manager.
Holds a medical degree from the Medical School of Ribeirão Preto, University of São Paulo (FMRP-USP), residency in Internal Medicine and Pulmonology and a PhD in Internal Medicine (Pulmonology) at FMRP-USP. He completed postdoctoral studies at the Meakins-Christie Laboratory, McGill, Canada. He is professor at the Internal Medicine Department of FMRP-USP, coordinator of the Laboratory of Experimental Pulmonary Pathophysiology, associate researcher at Center for Research in Inflammatory Diseases and director of the Regional Hospital of Serrana.
He received a B.S. summa cum laude from New York University in 1976, a Ph.D. degree from the Rockefeller University in 1981 and an M.D. degree from New York University Medical School in 1982. He joined the Department of Genetics at Harvard Medical School for postdoctoral training and in 1996 became professor at Rockefeller University. Nussenzweig’s laboratory studies the molecular aspects of the immune system’s innate and adaptive responses using a combination of biochemistry, molecular biology, and genetics.
Professor of Medicine at the Faculty of Medicine of USP, advisor for masters and Ph.D. degrees in Medical Sciences and Epidemiology. Works at University Hospital, coordinating the undergraduate course in medicine and the postgraduate course with courses in biostatistics and epidemiology. He directs the "USP Clinical and Epidemiological Research Center" and the EcoEpidemiology Initiative. He coordinates the RECOVIDA project and is one of the two initiators of the INFOVID collaborative network.
Principal Investigator at Facultad de Medicina Clinica Alemana Universidad del Desarrollo. Trained in Internal Medicine at Universidad de Chile and in Infectious Diseases at P. Universidad Católica de Chile. Master of Medical Sciences, Harvard University, Boston, MA, USA. Research lines: Emerging infectious diseases, vaccine effectiveness, and antimicrobial resistance
Professor of Biochemistry and Molecular Biology of the University of Barcelona, where he had the Molecular Neurobiology Laboratory, considered of excellence. His lab is involved in translational research concerning G protein-coupled receptors (GPCRs) and their therapeutic potential. Their research is in the frontier between Immunology and Neurology and in what concerns HIV and SARS-Cov-2, interested in viral coreceptors and in GPCRs involved in viral entry. Was visiting professor at the Immunology Division at Harvard Medical School and stayed at Pasteur Institute.
Member of the Permanent Advisory Board on Immunization Practices for the Ministry of Health in Brazil and current director of Brazilian Society Immunization, he has been working with immunization for more than 25 years. Chairman of the Department of Immunization for the Brazilian Society of Pediatrics and member of the Committee of Pediatric Infectious Diseases of São Paulo Pediatric Society, Dr. Kfouri has contributed with papers and book chapters on the subject of immunization and participated in investigation and DSMD of clinical trials in vaccines.
Previous Dean of the Hacettepe University School of Medicine in Ankara. Trained in Internal Medicine and infectious diseases from Hacettepe University and a fellowship in infectious diseases from New England Deaconess Hospital and Harvard Medical School. Was member of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), European Study Group of Nosocomial Infections, Director of the Hacettepe University AIDS Treatment and Research Center, Ankara AIDS Prevention Society, Ankara Microbiology Society, and the Turkish Society of Internal Medicine.
Pediatrician and epidemiologist focused on diseases of low and middle income countries. His work on HIV-HPV programs motivated a change in the 1993 CDC AIDS case surveillance definition and inspired cervical cancer screening programs launched within HIV/AIDS programs. Increasingly engaged in health policy, around HIV/AIDS programs and their expansion to non-communicable diseases, coronavirus pandemic response and prevention, and public health workforce development. Recently studied COVID-19 vaccine in Dominican Republic and Connecticut.
Associate Professor at Pontifical Catholic University in Chile and researcher associated with the Millennium Institute on Immunology and Immunotherapy, she earned her Medical Technologist degree in 1999 and her PhD in Biomedical Sciences in 2004 at the Chile University. Subsequently she joined as a post-doctoral fellow at Pontiﬁcia Universidad Católica de Chile during 2004–2007. As part of her training, Dr. Susan Bueno has performed scientiﬁc training at Texas A&M University, Albert Einstein College of Medicine and New York University.
President, and CEO of Sinovac Biotech Ltd., a professorate senior engineer. He has contributed to the field of disease control for nearly 40 years. As one of the first people to isolate Hepatitis A Virus (HAV) in China, he was also the first one who successfully developed inactivated hepatitis A vaccine. Since 2003, he has conducted the development of SARS inactivated vaccine, Pandemic influenza vaccine (H5N1), Pandemic influenza vaccine (H1N1), inactivated enterovirus 71 (EV71) vaccine, Covid-19 vaccine,and other national key projects.
Principal investigator and doctoral supervisor of the Key Laboratory of Infection and Immunity at the Institute of Biophysics of Chinese Academy of Sciences. Received his bachelor’s degree in biotechnology from Sichuan University and doctor’s degree from the Chinese Academy of Sciences. Has published more than 40 research articles in Science, Nature, Cell Host & Microbe, Nature Microbiology, among others, and led his scientific research team to participate in the research and development of inactivated SARS-CoV-2 vaccine CoronaVac.
Yaling Hu is currently the vice president of Sinovac Life Sciences Co., in charge of R&D operations. As a senior specialist expertized in vaccine development, she has presided over the R&D, clinical study, quality evaluation of a number of blockbuster vaccine products over the past ten years, including H1N1 Influenza A Vaccine (Split Virion), Inactivated-Panflu.1®; Enterovirus Type 71 Vaccine (Vero cell). Since January 2020, Hu led the R&D team of Sinovac to complete the pre-clinical research of the CoronaVac. Hu is the enterprise member of WHO expert group.
Chief AIDS expert of the Chinese Center for Disease Control and Prevention. Chairman of the Academic Comittee of the Center for STD and Aids Prevention Control. Chair Professor of Nankai University. Academician of the American Academy of Microbiology. For many years, he devoted himself to the research on the pathogenesis of AIDS, epidemiology and genetic diagnosis. He is an internationally renowned scientist in the field of AIDS research.
He studied Biological Science at Fudan University, in China, graduated in Systems Biology at Case Western Reserve University, in Cleveland. He has a PhD in Genetics, Genomics and Systems Biology from the University of Chicago and post-doctorate on RNA epigenetics in the Department of Chemistry at the University of Chicago. He is Professor and Principal Investigator of the Systems Biology Group at the State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan University, in Yunnan, China.
Graduated in Preventive Medicine from Harbin Medical University, finished Master of Public Health and Field Epidemiology Training Program from Chinese Center for Disease Control and Prevention. Focused on vaccine preventable disease and immunization program for 20 years, had working experience at provincial level CDC in China and WHO China office. Currently, he is deputy director and researcher of National Immunization Program at China CDC, involves several vaccine Technical Working Groups including COVID-19 in China CDC.